ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Acadia Pharma (ACAD) Tops Q2 EPS by 17c
August 5, 2020 4:57 PM EDTAcadia Pharma (NASDAQ: ACAD) reported Q2 EPS of ($0.27), $0.17 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $110 million versus the consensus estimate of $103.34 million.
At June 30, 2020, ACADIAs cash, cash equivalents, and investment securities totaled $658.6 million, compared to $697.4 million at December... More
